5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
Bone O
Marrow O
Suppression O
: O
Measure O
blood O
counts O
prior O
to O
treatment O
initiation O
and O
before O
every O
dose O
of O
Xofigo O
. O

Discontinue O
Xofigo O
if O
hematologic O
values O
do O
not O
recover O
within O
6 O
to O
8 O
weeks O
after O
treatment O
. O

Monitor O
patients O
with O
compromised O
bone O
marrow O
reserve O
closely O
. O

Discontinue O
Xofigo O
in O
patients O
who O
experience O
life-threatening O
complications O
despite O
supportive O
care O
measures O
. O

( O
5.1 O
) O
5.1 O
Bone O
Marrow O
Suppression O
In O
the O
randomized O
trial O
, O
2 O
% O
of O
patients O
on O
the O
Xofigo O
arm O
experienced O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
or O
ongoing O
pancytopenia B-OSE_Labeled_AE
compared O
to O
no O
patients O
treated O
with O
placebo O
. O

There O
were O
two O
deaths B-NonOSE_AE
due O
to O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
and O
for O
7 O
of O
13 O
patients O
treated O
with O
Xofigo O
, O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
was O
ongoing O
at O
the O
time O
of O
death B-NonOSE_AE
. O

Among O
the O
13 O
patients O
who O
experienced O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
, O
54 O
% O
required O
blood O
transfusions O
. O

Four O
percent O
( O
4 O
% O
) O
of O
patients O
on O
the O
Xofigo O
arm O
and O
2 O
% O
on O
the O
placebo O
arm O
permanently O
discontinued O
therapy O
due O
to O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
. O

In O
the O
randomized O
trial O
, O
deaths B-NonOSE_AE
related O
to O
vascular B-NonOSE_AE
hemorrhage I-NonOSE_AE
in O
association O
with O
myelosuppression B-NonOSE_AE
were O
observed O
in O
1 O
% O
of O
Xofigo-treated O
patients O
compared O
to O
0.3 O
% O
of O
patients O
treated O
with O
placebo O
. O

The O
incidence O
of O
infection B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
deaths B-NonOSE_AE
( O
2 O
% O
) O
, O
serious O
infections B-NonOSE_AE
( O
10 O
% O
) O
, O
and O
febrile B-NonOSE_AE
neutropenia I-NonOSE_AE
( O
< O
1 O
% O
) O
were O
similar O
for O
patients O
treated O
with O
Xofigo O
and O
placebo O
. O

Myelosuppression B-OSE_Labeled_AE
; O
notably O
thrombocytopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
and O
leukopenia B-OSE_Labeled_AE
; O
has O
been O
reported O
in O
patients O
treated O
with O
Xofigo O
. O

In O
the O
randomized O
trial O
, O
complete O
blood O
counts O
( O
CBCs O
) O
were O
obtained O
every O
4 O
weeks O
prior O
to O
each O
dose O
and O
the O
nadir O
CBCs O
and O
times O
of O
recovery O
were O
not O
well O
characterized O
. O

In O
a O
separate O
single-dose O
phase O
1 O
study O
of O
Xofigo O
, O
neutrophil O
and O
platelet O
count O
nadirs O
occurred O
2 O
to O
3 O
weeks O
after O
Xofigo O
administration O
at O
doses O
that O
were O
up O
to O
1 O
to O
5 O
times O
the O
recommended O
dose O
, O
and O
most O
patients O
recovered O
approximately O
6 O
to O
8 O
weeks O
after O
administration O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Hematologic O
evaluation O
of O
patients O
must O
be O
performed O
at O
baseline O
and O
prior O
to O
every O
dose O
of O
Xofigo O
. O

Before O
the O
first O
administration O
of O
Xofigo O
, O
the O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
( I-NonOSE_AE
ANC I-NonOSE_AE
) I-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/L O
, O
the O
platelet B-NonOSE_AE
count I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
and O
hemoglobin B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

Before O
subsequent O
administrations O
of O
Xofigo O
, O
the O
ANC B-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
and O
the O
platelet B-NonOSE_AE
count I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
. O

If O
there O
is O
no O
recovery O
to O
these O
values O
within O
6 O
to O
8 O
weeks O
after O
the O
last O
administration O
of O
Xofigo O
, O
despite O
receiving O
supportive O
care O
, O
further O
treatment O
with O
Xofigo O
should O
be O
discontinued O
. O

Patients O
with O
evidence O
of O
compromised B-NonOSE_AE
bone I-NonOSE_AE
marrow I-NonOSE_AE
reserve I-NonOSE_AE
should O
be O
monitored O
closely O
and O
provided O
with O
supportive O
care O
measures O
when O
clinically O
indicated O
. O

Discontinue O
Xofigo O
in O
patients O
who O
experience O
life-threatening O
complications O
despite O
supportive O
care O
for O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
safety O
and O
efficacy O
of O
concomitant O
chemotherapy O
with O
Xofigo O
have O
not O
been O
established O
. O

Outside O
of O
a O
clinical O
trial O
, O
concomitant O
use O
with O
chemotherapy O
is O
not O
recommended O
due O
to O
the O
potential O
for O
additive O
myelosuppression B-NonOSE_AE
. O

If O
chemotherapy O
, O
other O
systemic O
radioisotopes O
or O
hemibody O
external O
radiotherapy O
are O
administered O
during O
the O
treatment O
period O
, O
Xofigo O
should O
be O
discontinued O
. O

